SBIR-STTR Award

Membrane-Stabilized Lymphotoxin As a Vaccine Adjuvant
Award last edited on: 6/11/03

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$95,872
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Mark J Cantwell

Company Information

Tragen Pharmaceutics (AKA: Immunogenex Inc)

10150 Sorrento Valley Road Suite 100
San Diego, CA 92121
   (858) 623-2754
   cprussak@tragenpharm.com
   www.tragenpharmaceuticals.com
Location: Single
Congr. District: 52
County: San Diego

Phase I

Contract Number: 1R43AI052567-01A1
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2003
Phase I Amount
$95,872
Recent events have re-emphasized the need for the development of methods to potentiate or expand the stocks of currently available vaccines. This is especially true for those vaccines that protect against biological agents that have the greatest potential to inflict widespread morbidity and mortality, such as smallpox and anthrax. Available vaccines that target these biologic agents were developed decades ago and the anti-microbial protection these vaccines afford are rather limited. Furthermore, production of these vaccines was curtailed years ago and the availability of the remaining vaccine stocks is limited. Thus, there is an urgent need to identify adjuvant methods that either shorten the time required to achieve protective immunization or allow for immunization with either less vaccine or fewer injections per person, thereby effectively expanding the number of doses available with current vaccine stocks. To address this issue, Tragen Pharmaceuticals is developing novel adjuvants from members of the tumor necrosis factor family. One such adjuvant we have developed is a membrane-stabilized form of lymphotoxin. Through membrane-stabilization, Tragen Pharmaceuticals aims to increase the therapeutic activity of lymphotoxin while eliminating the systemic toxicity of the native form of this molecule that has prevented its use as a therapeutic product.

Thesaurus Terms:
antigen antibody reaction, immunomodulator, method development, tumor necrosis factor beta, vaccine development active immunization, cytotoxic T lymphocyte, humoral immunity, membrane structure, mucosal immunity, vaccinia virus laboratory mouse

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----